19. Revenues from Contracts and Significant Customers

Disaggregation of Total Revenues

The Company has seven marketed products, with the majority of sales from Targadox®, Luxamend®, Ceracade® and Exelderm®. Substantially all of the Company’s product revenues are recorded in the U.S. Substantially all of the Company’s collaboration revenues are from its collaboration with TGTX. Revenues by product and collaborator are summarized as follows:

Significant Customers

Commencing in the second quarter of 2018, the majority of our dermatology products are sold under a third party logistics (“3PL”) Title Model, and as such, one customer consistently accounts for over 80% of gross product revenue and AR.  Under a 3PL Title Model, the company sells product to a 3PL, who in turn, manages distribution and collections. 

For the three and six months ended June 30, 2019, gross product revenue under the 3PL Title Model accounted for approximately 84.0% and 86.0%, respectively.

For the three months ended June 30, 2018, two of the Company’s Dermatology Products customers each accounted for approximately 53.0% and 11.0% of total gross product revenue.

For the six months ended June 30, 2018, three of the Company’s Dermatology Products customers each accounted for approximately 27%,  16% and 12% of  total gross product revenue.

At June 30, 2019, one of the Company’s Dermatology Products customers accounted for approximately 77.0% of total gross accounts receivable.  At December 31, 2018, one of the Company’s Dermatology Products customers accounted for approximately 80% of total gross accounts receivable.